AB
Arie Belldegrun
Angel InvestorQuietBelldegrun is the Director of the Institute of Urologic Oncology and Professor and Chief of Urologic Oncology at the David Geffen School of ...
Los Angeles, United StatesFounded 2021
3
Investments
3
Exits
—
AUM
100.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Arie Belldegrun.
Investment Thesis & Strategy
As an angel investor, Arie Belldegrun likely invests in various stages and industries, potentially focusing on companies related to his expertise in urologic oncology. He may seek early-stage ventures with innovative solutions in the healthcare sector.
Investment Activity
Deals per year over the last 14 years
1
20060
20070
20080
20090
20100
20110
20120
20131
20140
20150
20160
20170
20181
2019Portfolio Companies
Selected investments from their portfolio of 3 companies
K
Kronos Bio
Biotech · Series A, 2019
K
Kite Pharma
Biotech · Series A, 2014
A
Arno Therapeutics
Biotech · Seed, 2006
Notable Exits
CompanyTypeYearValue / Acquirer
Arno TherapeuticsAcquisition2018—
Kronos BioAcquisition2018—
Kite PharmaAcquisition2017—
Frequently Asked Questions
Arie Belldegrun focuses on Seed stage investments.
Related Investors
Marlon Nichols
Los Angeles, United States · 102 deals
Adam Berger
Los Angeles, United States · 94 deals
Brandon Beck
Los Angeles, United States · 68 deals
Ashton Kutcher
Los Angeles, United States · 67 deals
David Mandel
Los Angeles, United States · 52 deals
A-Grade Investments
Los Angeles, United States · 49 deals